<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796366</url>
  </required_header>
  <id_info>
    <org_study_id>NN1953-4013</org_study_id>
    <secondary_id>2012-003046-32</secondary_id>
    <secondary_id>U1111-1132-0943</secondary_id>
    <nct_id>NCT01796366</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to investigate the safety,
      tolerability, pharmacokinetics (the exposure of the trial drug in the body) and
      pharmacodynamics (the effect of the investigated drug on the body) of NNC0123-0000-0338
      (insulin 338) in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2013</start_date>
  <completion_date type="Actual">August 19, 2013</completion_date>
  <primary_completion_date type="Actual">August 19, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events</measure>
    <time_frame>As recorded from first trial product administration (Day 1) and until Sub-visit 2A (Day 12) of the dosing visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum insulin concentration-time curve</measure>
    <time_frame>During one dosing interval (0-24 hours) at steady-state (Day 10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the glucose infusion rate-time curve</measure>
    <time_frame>During one dosing interval (0-24 hours) at steady state (Day 10)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin 338 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glargine + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin 338 (GIPET I)</intervention_name>
    <description>Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.</description>
    <arm_group_label>Insulin 338 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>S.c placebo administered in combination with insulin 338</description>
    <arm_group_label>Insulin 338 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.</description>
    <arm_group_label>Insulin glargine + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Oral placebo administered in combination with s.c. insulin glargine</description>
    <arm_group_label>Insulin glargine + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subject, or female subject of no childbearing potential, if surgically sterilized
             (i.e. tubal ligation, bilateral oopherectomies (removal of both ovaries and both
             fallopian tubes) or hysterectomised) for at least 3 months or if postmenopausal (i.e.
             as defined by amenorrhoea for at least 12 months prior to screening and documented by
             follicle stimulating hormone (FSH) levels above 40 U/L)

          -  Body mass index (BMI) between 20.0 and 35.0 kg/m^2 (both inclusive)

          -  Type 2 diabetes mellitus (as diagnosed clinically) for 12 months or more

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial products or related products

          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,
             vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the
             Investigator

          -  Any chronic disorder or severe disease which in the opinion of the Investigator might
             jeopardise subject's safety or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>February 28, 2017</last_update_submitted>
  <last_update_submitted_qc>February 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

